We all suffer if derivatives are treated like drugs

Regulators are clamping down on complexity, but risk harming innovation

david-rowe
David Rowe

I have written several times in the past about the role and potential dangers of complexity. Recent years have seen it become one of the animating themes in the prudential regulation of derivatives. Early last year, Avinash Persaud offered an informed and well-balanced discussion of the issue in the annual Financial Stability Review from the Banque de France.

Persaud points out that too much of the public discussion of capital markets regulation reflects little or no appreciation of the social

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here